Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16042893 | 0.87 | NOS3 (0.33) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL18225077 | 0.83 | EGFR (0.33) | EGFRLIPEJAK2BTK | |
| SCHEMBL13016581 | 0.83 | NOS3 (0.35) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL13089602 | 0.81 | NOS3 (0.47) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL30736300 | 0.81 | NOS3 (0.47) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL2814938 | 0.80 | LPL (0.34) | NOS3NOS1NOS2PDGFRBKDR | |
| Hydrochloric Acid SCHEMBL29960928 | 0.80 | NOS3 (0.46) | NOS3NOS1NOS2PDGFRBKDR | |
| SCHEMBL29434913 | 0.80 | MTOR (0.36) | PDGFRBKDREGFRLIPE | |
| SCHEMBL855843 | 0.80 | MTOR (0.36) | PDGFRBKDREGFRLIPE | |
| SCHEMBL26608466 | 0.79 | LIPE (0.36) | PDGFRBKDREGFRLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| EP-4168398-A1 | TYK-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-04-26 | — | — | EP | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
| EP-3235816-B1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10544137-B2 | PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (KR) | 2020-01-28 | — | — | US | disclosed |
| US-20190152964-A1 | PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| EP-3441387-A1 | PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | PIK3CA, PIK3CD, PIK3CG | NOS3 2996/4885NOS1 3520/4885NOS2 3564/4885 |
| US-10544137-B2 | PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof | PIK3R5, PIK3CD, PIK3CA | NOS3 2339/4885NOS1 2590/4885NOS2 2828/4885 |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | PIK3CA, PIK3CD, PIK3CG | NOS3 2996/4885NOS1 3520/4885NOS2 3564/4885 |
| US-20190152964-A1 | PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF | PIK3R5, PIK3CD, PIK3CA | NOS3 2339/4885NOS1 2590/4885NOS2 2828/4885 |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | NOS3 3168/4885NOS1 3750/4885NOS2 3913/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | NOS3 3843/4885NOS1 3484/4885NOS2 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.